Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease ; volume:14 ; number:1 ; day:27 ; month:9 ; year:2023 ; pages:1-8 ; date:12.2023
Nature Communications ; 14, Heft 1 (27.9.2023), 1-8, 12.2023
- Urheber
-
Yau, Kevin
Kurtesi, Alexandra
Qi, Freda
Delgado-Brand, Melanie
Tursun, Tulunay R.
Hu, Queenie
Dhruve, Miten
Kandel, Christopher
Enilama, Omosomi
Levin, Adeera
Jiang, Yidi
Hardy, W. Rod
Yuen, Darren A.
Perl, Jeffrey
Chan, Christopher T.
Leis, Jerome A.
Oliver, Matthew J.
Colwill, Karen
Gingras, Anne-Claude
Hladunewich, Michelle A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-023-41678-9
- URN
-
urn:nbn:de:101:1-2024020510151361978397
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yau, Kevin
- Kurtesi, Alexandra
- Qi, Freda
- Delgado-Brand, Melanie
- Tursun, Tulunay R.
- Hu, Queenie
- Dhruve, Miten
- Kandel, Christopher
- Enilama, Omosomi
- Levin, Adeera
- Jiang, Yidi
- Hardy, W. Rod
- Yuen, Darren A.
- Perl, Jeffrey
- Chan, Christopher T.
- Leis, Jerome A.
- Oliver, Matthew J.
- Colwill, Karen
- Gingras, Anne-Claude
- Hladunewich, Michelle A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters
Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters
Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters